• Explore /
  • Poster
  • / A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in subjects with HER-2 positive tumors.

A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in subjects with HER-2 positive tumors.

Abstract Poster

Authors

null

Brian Andrew Van Tine

Washington University in St. Louis, St. Louis, MO

Brian Andrew Van Tine , Minal A. Barve , Erika Paige Hamilton , Andrew Jacob Brenner , Zev A. Wainberg , Christine Burnett , Josh Pelham , Brigitte Brieschke , Thomas Strack

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04029922

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr TPS465)

Abstract #

TPS465

Poster Bd #

L9

Abstract Disclosures

Similar Posters

Poster

2020 Gastrointestinal Cancers Symposium

MT-5111: A novel HER2 targeting engineered toxin body in clinical development.

MT-5111: A novel HER2 targeting engineered toxin body in clinical development.

First Author: Roger J. Waltzman

First Author: Andrae L. Vandross

First Author: Zhi Peng

First Author: Sara A. Hurvitz